Table 3.
Cycle and pregnancy outcomes of the groups according to protocol
| Variable | Group 1 (n=109) | Group 2 (n=84) | Group 3 (n=79) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Agonist (n=83) | Antagonist (n=26) | p | Agonist (n=55) | Antagonist (n=29) | p | Agonist (n=61) | Antagonist (n=18) | p | |
| Cycle cancellation n (%) | 2 (2.4%) | 0 (0%) | NS | 0 (0%) | 5 (17.2%) | .004 | 2 (3.3%) | 0 (0%) | NS |
| Duration of stimulation (days) | 9.5±1.9 | 10.8±2.9 | NS | 9.2±2.4 | 10.3±2.0 | .016 | 10.3±3.0 | 10.5±2,4 | NS |
| Total gonadotropin dose (IU) | 1567.0±574.3 | 1532.8±798.1 | NS | 1727.8±663.6 | 1738.1±657.8 | NS | 2109.6±833.5 | 2044.4±679.3 | NS |
| No. of total oocytes | 18.4±9.4 | 15.4±7.6 | NS | 16.3±7.4 | 18.0±9.6 | NS | 14.9±7.3 | 10.1±4.7 | .010 |
| No. of mature oocytes | 13.5±6.6 | 10.5±6.3 | NS | 11.5±6.2 | 12.6±8.0 | NS | 10.4±5.3 | 6.6±4.2 | .010 |
| Severe OHSS | 6 (7.2%) | 2 (7.7%) | NS | 4 (7.3%) | 1 (3.4%) | NS | 0 (0%) | 0 (0%) | NS |
| Fertilization rate (%) | 44.5±21.5 | 41.1±22.6 | NS | 42.4±19.7 | 44.7±24.2 | NS | 48.3±23.5 | 40.2±30.9 | NS |
| Implantation rate/ET (%) | 36 (54.5%) | 11 (44.0%) | NS | 26 (51.0%) | 10 (50.0%) | NS | 19 (38.8%) | 5 (41.7%) | NS |
| Biochemical pregnancy/ET n (%) | 5 (7.6%) | 3 (12.0%) | NS | 8 (15.7%) | 2 (10.0%) | NS | 6 (12.2%) | 0 (0.0%) | NS |
| Clinical pregnancy/ET n (%) | 31 (47.0%) | 8 (32.0%) | NS | 18 (35.3%) | 8 (40.0%) | NS | 13 (26.5%) | 5 (41.7%) | NS |
| Miscarriage/ET n (%) | 11 (16.7%) | 2 (8.0%) | NS | 6 (11.8%) | 2 (10.0%) | NS | 4 (8.2%) | 2 (16.7%) | NS |
| Ongoing pregnancy/ET n (%) | 20 (30.3%) | 6 (24.0%) | NS | 12 (23.5%) | 6 (30.0%) | NS | 9 (18.4%) | 3 (25.0%) | NS |
| Multiple pregnancy/ET n (%) | 8 (12.1%) | 0 (0.0%) | NS | 3 (5.9%) | 1 (5.0%) | NS | 4 (8.2%) | 1 (8.3%) | NS |
Data are expressed as mean±SD.
No: number; OHSS: ovarian hyperstimulation syndrome; ET: embryo transfer